1492 Capital Management’s PTC Therapeutics PTCT Stock Holding History

1492 Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-15,580	Closed	-$109K	–	110
2016 Q2	$109K	Sell	15,580 -1,372	-8%	-$10.1K	0.1%	102
2016 Q1	$109K	Sell	16,952 -590	-3%	-$10.2K	0.09%	101
2015 Q4	$568K	Sell	17,542 -1,613	-8%	-$47.5K	0.41%	58
2015 Q3	$511K	Sell	19,155 -14	-0.1%	-$599	0.36%	71
2015 Q2	$923K	Buy	19,169 +5,998	+46%	+$350K	0.58%	46
2015 Q1	$801K	Sell	13,171 -1,072	-8%	-$65.4K	0.46%	57
2014 Q4	$737K	Buy	+14,243	New	+$627K	0.46%	64

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

1492 Capital Management's PTCT Position: Q3 2016 in Review

1492 Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2016, closing a stake of 15,580 shares — an estimated $109K sold.

1492 Capital Management first reported a position in PTCT in Q4 2014 and held it in 7 quarters. The position peaked at $923K in Q2 2015. 115 funds tracked by Wall St. Rank hold PTCT as of Q3 2016.

1492 Capital Management reported no remaining PTC Therapeutics position as of Q3 2016 after selling out during the quarter.
1492 Capital Management sold 15,580 PTC Therapeutics shares in Q3 2016, an estimated $109K.
1492 Capital Management first reported a position in PTC Therapeutics in Q4 2014 and held it in 7 quarters.
1492 Capital Management's PTC Therapeutics position peaked at $923K in Q2 2015.
115 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2016.

Based on 1492 Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.